Abstract: An ostomy appliance wafer has a skin facing layer of adhesive applied to a proximal side of a film layer to define a proximal skin facing surface of the ostomy appliance wafer, and the skin facing layer of adhesive has a thickness in a range between 25 to 200 micrometers.

Abstract: The invention relates to a method of separating and purifying products from a hydrothermal and/or solvothermal conversion process of carbonaceous material adapted to convert a feed stream comprising carbonaceous material at a pressure of at least 100 bar and a temperature of at least 300° C., where the converted feed stream (product mixture) comprises a mixture of CO2 containing gas, an oil phase, an aqueous phase comprising water soluble organics and dissolved salts, and inorganic solid phase; where the product mixture is cooled to a temperature in the range 40 to 250° C.

Abstract: The present invention relates to peptides and peptide analogues with high affinity for the PDZ domains of PICK1. The peptide or peptide analogue interacts with PICK1, blocking the native protein-protein interactions between PICK1 and its natural ligands. The invention furthermore relates to the therapeutic use of these peptides and peptide analogues in prevention and/or treatment of diseases and disorders associated with maladaptive plasticity, drug addiction and neuropathic pain.

Abstract: An ostomy appliance wafer has a skin facing layer of adhesive applied to a proximal side of a film layer to define a proximal skin facing surface of the ostomy appliance wafer, and the skin facing layer of adhesive has a thickness in a range between 25 to 200 micrometers.

Abstract: A device for collection waste from a body includes a collecting pouch and an adhesive wafer connected to the collecting pouch for attaching the collecting pouch to the body. The adhesive wafer includes at least one intermediate layer of adhesive, a skin facing layer of adhesive, a first film layer, and a second film layer. The first film layer is formed of backing layer material, and is positioned between the skin facing layer of adhesive and the intermediate layer of adhesive. The second film layer is formed of backing layer material. The second film layer is positioned adjacent to the intermediate layer of adhesive on an opposite side of the intermediate layer of adhesive from the first film layer. The first film layer is configured to reduce a peel force of the adhesive wafer.

Abstract: The invention relates to a method for the production of a rigid PIR foam composite containing man-made vitreous fibres (MMVF), the method comprising: providing MMVF, wherein at least 50% of the fibres by weight have a length of less than 250 ?m; providing a polyol component; mixing the MMVF and polyol component in a ratio such that the amount of MMVF is at least 10% by weight based on total weight of polyol component; emulsifying pentane with the mixture of polyol component and MMVF; inducing foam formation by addition of a further component which comprises isocyanate.

Abstract: A configuration deployment system stores configuration settings for a plurality of applications disposed at one or more computing hosts. The configuration settings are stored in a versioned repository and are organized in a hierarchical namespace structure. To deploy the configuration settings, a deployment service monitors the configuration settings at the configuration repository and identifies when a new configuration setting or a new version of an existing configuration setting is available in the configuration repository. The new configuration setting is transmitted to a computing device for use in an application. The application applies the changed configuration setting upon verifying that the change is compatible with the application.

Abstract: The present invention relates to benzoxazolone derivatives as acid ceramidase inhibitors, pharmaceutical compositions containing these inhibitors and methods of inhibiting acid ceramidase for the treatment of disorders in which modulation of the levels of ceramide is clinically relevant. The invention also provides benzoxazolone derivatives for use as a medicament in the treatment of cancer, inflammation, pain, inflammatory pain or pulmonary diseases.

Abstract: The present invention relates to substituted benzoxazolone derivatives as acid ceramidase inhibitors, pharmaceutical compositions containing these inhibitors and methods of inhibiting acid ceramidase for the treatment of disorders in which modulation of the levels of ceramide is clinically relevant. The invention also provides substituted benzoxazolone derivatives for use in the treatment of cancer, inflammation, pain, inflammatory pain or pulmonary diseases.

Abstract: The present invention is directed to the provision of small molecule inhibitors of the PSD-95/NMDA receptor interaction, employing an undecapeptide corresponding to the C-terminal of the NMDA as a template for finding lead candidates. A compound (NMDAR/PSD-95 inhibitor) of the invention includes a peptide or peptide analog comprising at least four peptide bonded residues having the sequence YTXV or YSXV, wherein Y is selected from among E, Q, and A, or an analog thereof, and X is selected from among A, Q, D, N, N-Me-A, N-Me-Q, N-Me-D, and N-Me-N or an analog thereof, wherein an amino-terminal residue of the peptide is N-alkylated.

Abstract: Disclosed is an ostomy bag 1 having an outer rotatable adhesive fitting wafer 15 attached thereto. This offers a higher degree of customization to the user, as the user may cut the adhesive fitting wafer in such a way that it fits to the contour of the skin and the user may also rotate the ostomy bag relative to the wafer in order to achieve a desired orientation of the ostomy bag.

Abstract: The present invention relates to benzoxazolone derivatives as acid ceramidase inhibitors, pharmaceutical compositions containing these inhibitors and methods of inhibiting acid ceramidase for the treatment of disorders in which modulation of the levels of ceramide is clinically relevant. The invention also provides benzoxazolone derivatives for use as a medicament in the treatment of cancer, inflammation, pain, inflammatory pain or pulmonary diseases.

Abstract: The present invention relates to substituted benzoxazolone derivatives as acid ceramidase inhibitors, pharmaceutical compositions containing these inhibitors and methods of inhibiting acid ceramidase for the treatment of disorders in which modulation of the levels of ceramide is clinically relevant. The invention also provides substituted benzoxazolone derivatives for use in the treatment of cancer, inflammation, pain, inflammatory pain or pulmonary diseases.

Abstract: An adhesive wafer for attaching a waste collecting pouch to a body includes a backing layer, a skin-facing adhesive layer, and an absorbing adhesive layer. The skin-facing adhesive is liquid impermeable and has a water absorption capacity less than 8 weight % and a moisture vapor transmission rate (MTVR) at least as high as 150 g/m2/24 h. The absorbing adhesive layer is disposed between the backing layer and the skin-facing adhesive layer. The absorbing adhesive layer has a water absorption capacity at least as high as 15 weight %.

Abstract: A body waste collecting device includes a collecting pouch and an adhesive wafer for attachment to the body. The adhesive wafer includes a backing layer, a first adhesive and a second adhesive. The second adhesive includes a polar plasticizing oil or a combination of polar plasticizing oils in the content of above 10% (w/w) of the second adhesive, and at least one polar polyethylene copolymer, where the content of the polyethylene copolymer is 10-50% (w/w) of the second adhesive, and the polyethylene copolymer has a melt flow index below 2 g/10 min (190° C./21.1N).

Abstract: A body waste collecting device comprising an adhesive composite that fastens a collecting bag to the skin is disclosed. The adhesive composite is highly moisture resistant while still being water absorbing. The adhesive composite comprises at least three layers, a backing layer, a moisture absorbing layer and a thin layer of vapor permeable, low-absorbing adhesive layer.

Abstract: The invention relates to a method for the production of a rigid PIR foam composite containing man-made vitreous fibres (MMVF), the method comprising: providing MMVF, wherein at least 50% of the fibres by weight have a length of less than 250 ?m; providing a polyol component; mixing the MMVF and polyol component in a ratio such that the amount of MMVF is at least 10% by weight based on total weight of polyol component; emulsifying pentane with the mixture of polyol component and MMVF; inducing foam formation by addition of a further component which comprises isocyanate.

Abstract: The present invention provides fatty acid derived compounds capable of binding to the PDZ domains of PSD-95 and their medical use as inhibitors of protein-protein interaction mediated by PSD-95.

Abstract: A wafer adapted for use with an ostomy appliance includes a backing layer, an adhesive layer applied to the backing layer and providing an adhesive surface, and a liner system disposed over an entirety of the adhesive surface. The adhesive surface includes a mid-section. The liner system includes a first side liner placed on a first lateral side of the mid-section of the adhesive surface, a second side liner placed on a second lateral side of the mid-section of the adhesive surface, and a third middle liner having folded edge portions and covering the mid-section of the adhesive surface.

Abstract: The present invention is directed to the provision of small molecule inhibitors of the PSD-95/NMDA receptor interaction, employing an undecapeptide corresponding to the C-terminal of the NMDA as a template for finding lead candidates. A compound (NMDAR/PSD-95 inhibitor) of the invention includes a peptide or peptide analogue comprising at least four peptide bonded residues having the sequence YTXV or YSXV, wherein Y is selected from among E, Q, and A, or an analogue thereof, and X is selected from among A, Q, D, N, N-Me-A, N-Me-Q, N-Me-D, and N-Me-N or an analogue thereof, wherein an amino-terminal residue of the peptide is N-alkylated.